ClinicalTrials.Veeva
Menu

Find clinical trials for Breast Cancer in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Breast Cancer trials near Hanyang, Seoul, KOR:

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07)

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...

Active, not recruiting
Metastatic Breast Cancer
Drug: Tucatinib
Drug: Durvalumab

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 71 other locations

This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab
Drug: Trastuzumab deruxtecan

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Seoul, Korea, Republic of and 226 other locations

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd...

Enrolling
HER2 Positive Metastatic Breast Cancer
Drug: ARX788

Phase 2

Ambrx

Seoul, Korea, Republic of and 62 other locations

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....

Enrolling
Advanced Breast Cancer
Drug: Fulvestrant
Drug: ARV-471

Phase 3

Pfizer
Pfizer

Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of and 324 other locations

DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other ther ...

Active, not recruiting
Metastatic Breast Cancer
Drug: Fulvestrant
Drug: Durvalumab

Phase 1

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 36 other locations

look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...

Active, not recruiting
HER2-positive Early Breast Cancer
Breast Cancer
Drug: Pertuzumab
Drug: Paclitaxel

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 147 other locations

To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and Taxol® (IV paclitaxel) on recurrent or metastatic breast...

Active, not recruiting
Recurrent or Metastatic Breast Cancer
Drug: Oral paclitaxel
Drug: Paclitaxel injection

Phase 2, Phase 3

Daehwa Pharmaceutical

Seoul, Korea, Republic of and 50 other locations

with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of...

Active, not recruiting
Breast Cancer
Drug: Vinorelbine
Drug: Eribulin

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 166 other locations

Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatmen...

Active, not recruiting
Breast Cancer
Drug: DS-8201a

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Seoul, Korea, Republic of and 98 other locations

OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), ph...

Enrolling
Advanced Cancer
Breast Cancer
Drug: Trastuzumab
Drug: Fulvestrant

Phase 1

OnKure

Seoul, Korea, Republic of and 8 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems